|10.66||+0.0800||+0.76%||Vol 8.40K||1Y Perf -|
|Sep 20th, 2023 15:59 DELAYED|
|- -||- -%|
|Target Price||-||Analyst Rating||— — 0.00|
|Potential %||-||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||53.70||Earnings Rating||—|
|Market Cap||68.54M||Earnings Date||-|
Today's Price Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||102|
|Avg. Monthly Volume||136|
|Avg. Quarterly Volume||1.16K|
Bellevue Life Sciences Unit 1 Com & Wt Exp (NASDAQ: BLACU) stock closed at 10.66 per share at the end of the most recent trading day (a 0.76% change compared to the prior day closing price) with a volume of 8.40K shares and market capitalization of 0.0000. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Diversified Financial Services industry, Financial Services sector and employs 0 people. Bellevue Life Sciences Unit 1 Com & Wt Exp CEO is .
The one-year performance of Bellevue Life Sciences Unit 1 Com & Wt Exp stock is %, while year-to-date (YTD) performance is %. BLACU stock has a five-year performance of %. Its 52-week range is between 10.1496 and 11.1, which gives BLACU stock a 52-week price range ratio of 53.70%
Bellevue Life Sciences Unit 1 Com & Wt Exp currently has a PE ratio of -, a price-to-book (PB) ratio of -, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -0.64%, a ROC of -% and a ROE of 709.87%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $- revenue per share.
Of the last four earnings reports from Bellevue Life Sciences Unit 1 Com & Wt Exp, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Bellevue Life Sciences Unit 1 Com & Wt Exp’s next earnings report date is -.
The consensus rating of Wall Street analysts for Bellevue Life Sciences Unit 1 Com & Wt Exp is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Bellevue Life Sciences Unit 1 Com & Wt Exp stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Bellevue Life Sciences Unit 1 Com & Wt Exp has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Bellevue Life Sciences Unit 1 Com & Wt Exp has a Neutral technical analysis rating based on Technical Indicators (ADX : 35.17, ATR14 : 0.02, CCI20 : 197.81, MACD : 0.02, Money Flow Index : 89.11, ROC : 0.95, RSI : 69.82, STOCH (14,3) : 100.00, STOCH RSI : 1.00, UO : 96.26, Williams %R : 0.00), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Bellevue Life Sciences Unit 1 Com & Wt Exp in the last 12-months were: Kuk Hyoun Hwang (Buy at a value of $4 300 000)
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.